Treatment plan
toxicity, emesis, malignancy, infections, pain, tumour
DISEASE, TUMOUR, COMPLICATIONS, INFECTIONS
The backbone of the chemotherapy for both phase I and II parts of the study was weekly topotecan 4 mg/mPatients in the phase II received pazopanib in the dose as determined by the phase I trial. In case of complete or partial response or stable disease the pazopanib therapy could be maintained until development of unacceptable toxicity or tumour progression according the RECIST criteria. Patients who discontinued drug therapy early were observed for 12 months from end of chemotherapy. Concomitant therapies with supportive or other medications as transfusions of fresh frozen plasma and blood components were allowed to treat emesis, pain, infections and other complications of the malignancy and treatment.